Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Specialty Channel

Acute Myeloid Leukemia
Specialty Channel
Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for Acute Myeloid Leukemia
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for Relapsed/Refractory Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax...
01/12/2026
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
Quiz
Venetoclax Plus Azacitidine for Relapsed AML
10/30/2025
Emily Estrada
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax...
10/30/2025
Oncology
News
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
10/30/2025
Emily Estrada
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the...
10/30/2025
Oncology

News

News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for Relapsed/Refractory Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax...
01/12/2026
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
News
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
10/30/2025
Emily Estrada
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the...
10/30/2025
Oncology
FDA Approval
FDA Grants Approval to Revumenib for Patients With R/R NPM1-Mutated Acute Myeloid Leukemia
10/24/2025
Emily Estrada
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug...
10/24/2025
Oncology
News
PD-1 Inhibitor Plus Azacitidine and HAG Regimen Demonstrates Promising Activity for R/R Acute Myeloid Leukemia
10/02/2025
Emily Estrada
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a...
10/02/2025
Oncology
News
Ruxolitinib and Decitabine With Modified Busulfan/Cyclophosphamide Conditioning Treatment Tolerable, Reduces Relapse for High-Risk AML/MDS
10/02/2025
Emily Estrada
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to...
10/02/2025
Oncology

Interactive Features

Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for Acute Myeloid Leukemia
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
Quiz
Venetoclax Plus Azacitidine for Relapsed AML
10/30/2025
Emily Estrada
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax...
10/30/2025
Oncology
Quiz
Survival Outcomes of Patients With AML and Concurrent DNMT3A & TET2 Mutations
10/02/2025
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with concurrent DNMT3A and TET2 mutations and acute myeloid leukemia demonstrated superior treatment responses and survival outcomes compared to patients without mutations, according to a retrospective analysis.
True or False: Patients with...
10/02/2025
Oncology
Quiz
Venetoclax and CPX-531 for R/R AML
08/25/2025
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2...
08/25/2025
Oncology
Quiz
Ziftomenib Monotherapy for R/R NPM1-Mutant AML
08/13/2025
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to results from the phase 2 KOMET-001 trial, ziftomenib demonstrated promising efficacy and safety among patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
True or False: According to...
08/13/2025
Oncology
Quiz
Olutasidenib for R/R IDH1-Mutant AML
07/17/2025
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis evaluating olutasidenib for R/R IDH1-mutant AML, patients treated earlier in the treatment sequence (after 1 to 2 prior regimens) demonstrated which overall response rate?
In the post hoc analysis...
07/17/2025
Oncology
Quiz
Tislelizumab Plus HMA and CAG for Relapsed/Refractory AML
06/16/2025
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial...
06/16/2025
Oncology
Quiz
Combination Iadademstat and Azacitidine for Patients With Patients With Newly Diagnosed AML
09/25/2024
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to results from the phase 2a, dose-finding ALICE study, the frontline combination of iadademstat and azacitidine failed to produce promising responses among patients with newly diagnosed acute myeloid leukemia,...
True or False: According to...
09/25/2024
Oncology

Recent Stories

Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for Acute Myeloid Leukemia
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for Relapsed/Refractory Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax...
01/12/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use